Henry G. Grabowski

Professor Emeritus of Economics

External Address: 
242 Social Sciences, Box 90097, Durham, NC 27708
Internal Office Address: 
Box 90097
(919) 660-1839

Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis” with John Vernon and Lacy Glenn Thomas, to his more recent projects including, “Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention” with Jeffrey L. Moe. His latest research studies include other such titles as, “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity” with Margaret Kyle; “Should the Patent System for New Medicines Be Abolished?” with J.A. DiMasi; and several others. Professor Grabowski has served as an advisor and consultant to various organizations, offering his ideas and insights gained through his extensive investigations to the National Trade Academy of Sciences, the Institute of Medicine, the Office of Technology Assessment, the Federal Trade Commission, and the General Accounting Office. His latest project involved an analysis for the FTC concerning public policy, competition and investment in the “Next Generation of Biologics.”


  • Ph.D., Princeton University 1967
  • M.A., Princeton University 1964
  • B.S., Lehigh University 1962

Grabowski, HG. "FDA in the Twenty-First Century." In FDA Regulation Of Biosimilars,edited by G Cohen, and H Lynch,414-430. Columbia University Press, 2015. (Chapter) Open Access Copy

Grabowski, HG, Long, G, and Mortiner, R. "Biosimilars." In Encyclopedia of Health Economics,edited by A Culyer. Elsevier, 2014. (Chapter)

Grabowski, HG. "Public Policy and Innovation in Pharmaceuticals and Biotechnology." In Business and Economics for the 21st Century Volume 1,edited by D Kantarelis,343-349. Worcester, MA: Business and Economic Society International, 1997. (Chapter)

Skinner, MW, Hedlund Hoppe, PA, Grabowski, HG, Manning, R, Tachdjian, R, Crone, JF, and Youngner, SJ. "Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products." Transfusion 56, no. 11 (November 2016): 2889-2894. Full Text Open Access Copy

Grabowski, H, Long, G, Mortimer, R, and Boyo, A. "Updated trends in US brand-name and generic drug competition." Journal of Medical Economics 19, no. 9 (September 2016): 836-844. Full Text Open Access Copy

Grabowski, HG, and Manning, RL. "An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors." International Journal of the Economics of Business 23, no. 2 (May 3, 2016): 149-166. Full Text Open Access Copy

DiMasi, JA, Grabowski, HG, and Hansen, RW. "Innovation in the pharmaceutical industry: New estimates of R&D costs." Journal of health economics 47 (May 2016): 20-33. Full Text Open Access Copy

Lietzan, EF, and Grabowski, HG. "FDA Regulation of Biosimilars." (September 16, 2015).

DiMasi, JA, Grabowski, HG, and Hansen, RW. "The cost of drug development." The New England journal of medicine 372, no. 20 (May 2015): 1972-. Full Text Open Access Copy

Grabowski, HG, DiMasi, JA, and Long, G. "The roles of patents and research and development incentives in biopharmaceutical innovation." Health affairs (Project Hope) 34, no. 2 (February 2015): 302-310. Full Text Open Access Copy

Grabowski, HG, Guha, R, and Salgado, M. "Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future." Health affairs (Project Hope) 33, no. 6 (June 2014): 1048-1057. Full Text Open Access Copy

Grabowski, H, Guha, R, and Salgado, M. "Biosimilar competition: lessons from Europe." Nature Reviews Drug Discovery 13, no. 2 (January 21, 2014): 99-100. Full Text Open Access Copy

Grabowski, HG, Long, G, and Mortimer, R. "Recent Trends in Brand-Name and Generic Drug Competition." Journal of Medical Economics (2013): 1-8. Open Access Copy